vimarsana.com
Home
Live Updates
Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC : vimarsana.com
Preliminary Data Show Improved Responses with Cetuximab Plus Divarasib in KRAS G12C–mutated CRC
Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Related Keywords
Australia ,
Melbourne ,
Victoria ,
Roche Genentech ,
Pierre Fabre ,
Jayesh Desai ,
Astrazeneca Medimmune ,
Daiichi Sankyo Europe Gmb ,
Phasei Early Drug Development Program ,
University Of Melbourne ,
Merck Kga ,
Novartis ,
Glaxosmithkline ,
Amgen ,
Sir Peter Maccallum Department Of Oncology ,
Peter Maccallum Cancer Centre ,
Merck Kgaa ,
Boehringer Ingelheim ,
Bristol Myers Squibb ,
Pfizer ,
Early Drug Development Program ,
Peter Maccallum Cancer ,
Sir Peter Maccallum Department ,
Daiichi Sankyo Europe Gmbh ,
Cetuximab Plus Divarasib ,
Bbs ,
Racp ,
Patients With Kras G12c Mutated Colorectal Cancer ,
vimarsana.com © 2020. All Rights Reserved.